Mesothelioma.com Resources for Patients and their Families

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Brief Summary

The purpose of this signal seeking study is to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.

Tracking Information
First Received DateJuly 9, 2014
Last Changed DateApril 28, 2017
Start DateAugust 25, 2014
Anticipated Primary Completion DateApril 15, 2018
Primary Outcome Measures

Clinical benefit rate associated with LEE011 treatment [Time Frame: 16 weeks]

Secondary Outcome Measures

Overall Response (OR) of Partial Response (PR) or greater [Time Frame: Baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months]

Progression Free Survival (PFS) [Time Frame: Every 8 weeks until death, assessed up to 24 months]

Overall Survival (OS) [Time Frame: Every 8 weeks until death, assessed up to 36 months]

Duration of Response (DOR) [Time Frame: Baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months]

Safety and tolerability [Time Frame: Baseline up to 30 days after last study treatment]

Descriptive Information
PhasePhase 2
Study TypeInterventional
Condition
  • Tumors With CDK4/6 Pathway Activation
Intervention
  • Drug: LEE011
Study Arms / Comparison Groups1 / 0
Recruitment Information
Recruitment StatusActive, not recruiting
Actual Enrollment106
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Patient has a confirmed diagnosis of a select solid tumor (except breast cancer (however, triple negative will be included), liposarcoma, CRPC, melanoma and teratoma) or hematological malignancy (except mantle cell lymphoma).

- Patient must have been pre-identified as having a tumor with CDK4 amplification or mutation, CDK6 amplification or mutation, Cyclin D1 (CCND1) amplification, Cyclin D3 (CCND3) amplification, or p16 (CDKN2A) mutation

- Patient has received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.

- Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.

- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion Criteria:

- Patients has received prior treatment with LEE011.

- Patient has clinically significant resting bradycardia (heart rate < 50 at rest), tachycardia (heart rate > 90 at rest), PR interval > 220 msec, QRS interval > 109 msec, or QTcF > 450 msec.

- Patients has primary CNS tumor or CNS tumor involvement

- Patient has received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug

Administrative Information
NCTIDNCT02187783
Responsible Party,
SponsorNovartis Pharmaceuticals
Verification DateApril 2017
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

Surviving Peritoneal Mesothelioma: Stephen Jay Gould’s Cancer Journey

Understanding Cancer Clinical Trials

Quest for a Cure: MCA Supports Cancer Research Month

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: